Literature DB >> 26817427

Emergency Management of Malignancy-Associated Hypercalcemia.

Bethany Dellay1, Meghan Groth.   

Abstract

The most common cause of hypercalcemia in the emergency department (ED) is malignancy-associated hypercalcemia (MAH), which can be caused by direct bone resorption from bone metastases, vitamin D secreting malignancies, and increased parathyroid hormone (PTH) or PTH-related protein (PTHrP) levels. Malignancy-associated hypercalcemia is associated with a very poor prognosis, with half of the patients dying within a month of diagnosis. Management consists of adequate hydration, bisphosphonate therapy, and correction of other abnormal electrolyte levels. Currently, no therapies have demonstrated an effect on mortality and are therefore viewed only as a means of stabilizing the patient until the underlying condition can be treated. All MAH patients should receive an oncology consult as soon as possible so they are able to receive treatment for the causative malignancy and increase their chance of survival.

Entities:  

Mesh:

Year:  2016        PMID: 26817427     DOI: 10.1097/TME.0000000000000093

Source DB:  PubMed          Journal:  Adv Emerg Nurs J        ISSN: 1931-4485


  4 in total

1.  Kasabach-Merritt syndrome combined with hypercalcemia: A case report.

Authors:  Runying Zou; Fang Peng; Tian Yu; Saizhen Zeng; Yalan You; Keke Chen; Hui Zou; Xin Tian; Chengguang Zhu; Xiangling He
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

Review 2.  Seizures Associated With Bone Density Conservation Agents.

Authors:  Kuan Sturgill; Justin P Reinert
Journal:  J Pharm Technol       Date:  2022-01-26

3.  Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer.

Authors:  Waleed Kian; Dina Levitas; Wafeek Alguayn; Walid Shalata; Adam A Sharb; Daniel Levin; Laila C Roisman; Margarita Tokar; Nir Peled; Alexander Yakobson
Journal:  JTO Clin Res Rep       Date:  2020-02-12

4.  Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients.

Authors:  Li Bao; Yutong Wang; Minqiu Lu; Bin Chu; Lei Shi; Shan Gao; Lijuan Fang; Qiuqing Xiang
Journal:  Cancer Med       Date:  2020-11-04       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.